Canaccord raised the firm’s price target on Globus Medical to $71 from $67 and keeps a Buy rating on the shares. The firm noted during the Q3 call, GMED increased its 2023 revenue guidance while reaffirming non-GAAP EPS guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMED:
- Globus Medical price target lowered to $53 from $60 at Morgan Stanley
- Globus Medical price target lowered to $53 from $58 at Truist
- Globus Medical backs FY23 EPS view $2.30, consensus $2.32
- Globus Medical reports Q3 EPS 57c, consensus 54c
- Globus Medical Reports Third Quarter 2023 Results
Questions or Comments about the article? Write to editor@tipranks.com